Table 7.
Summary of exposure to pazopanib for Cohorts A, B, and C – All-treated population
| Cohort A | Cohort B | Cohort C | ||||
|---|---|---|---|---|---|---|
| Pazopanib (800 mg QD) + pembrolizumab (2 mg/kg Q3W) (N=10) |
Pazopanib (600 mg QD) + pembrolizumab (2 mg/kg Q3W) (N=10) |
Pazopanib (at the final dose of the run-in) + pembrolizumab (2 mg/kg Q3W) (N=6) n (%) |
Pembrolizumab (2 mg/kg Q3W) (N=4) n (%) |
Pazopanib (at the final dose of the run-in) (N=11) n (%) |
||
| Patient daily dose (mg) a | Mean (SD) | 568.4 (224.52) | 503.9 (120.26) | 610.7 (189.43) | 706.3 (187.50) | 691.6 (110.36) |
| Median Min-max |
586.9 238–800 |
556.6 265–600 |
610.9 335–800 |
800.0 425–800 |
688.4 538–800 |
|
| Time on study treatment (months) b | Mean (SD) Median |
8.0 (7.43) 4.4 |
10.5 (13.29) 3.3 |
12.3 (8.32) 11.4 |
1.8 (0.19) 1.9 |
2.0 (1.15) 1.9 |
| Min-max <3 months |
1–23 3 (30) |
1–41 5 (50) |
4–25 0 |
2–2 4 (100) |
0–4 9 (82) |
|
| Time on study treatment categories, n (%) | 3 to <6 months 6 to <12 month s |
3 (30) 1 (10) |
1 (10) 1 (10) |
2 (33) 1 (17) |
0 0 |
2 (18) 0 |
| 12 to <18 months ≥18 months |
2 (20) 1 (10) |
0 3 (30) |
2 (33) 1 (17) |
0 0 |
0 0 |
|
a
The patient daily dose (the cumulative dose divided by the duration of exposure) was calculated for each patient first, and the summary statistics were calculated based on the patient’s average daily dose.
b
The time on study drug does not exclude dose interruptions.
max, maximum; min, minimum; Q3W, every 3 weeks; QD, once daily; SD, standard deviation.